Cover Image
市場調查報告書

中國的Tiotropium bromide市場分析

Investigation Report on China Tiotropium Bromide Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 297269
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中國的Tiotropium bromide市場分析 Investigation Report on China Tiotropium Bromide Market, 2010-2019
出版日期: 2015年06月04日 內容資訊: 英文 20 Pages
簡介

和全球各國同樣,中國大氣污染也惡化了,氣喘和慢性阻塞性肺病(COPD)的患者數增加,因此擴大了相關治療藥的市場機會。Boehringer Ingelheim Group開發的使用Tiotropium bromide的治療藥「Spiriva」,2002年6月受荷蘭、菲律賓認可,中國也在2006年受認可。該產品的銷售額在全球2013年到達了近50億美元。還有調查對象的醫院用Tiotropium bromide的銷售額,在2006∼2014年之間,以年複合成長率90%推移,達到了1,400萬元。今後由於產業發展和環境問題的解決延遲,氣喘、慢性阻塞性肺病的患者數持續增加,一般預期Tiotropium bromide的市場規模也將持續擴大。

本報告提供中國的Tiotropium bromide的市場相關分析、中國國內的產量及醫院用銷售額、價格趨勢(過去5年份)、各企業、各投藥形態的市場佔有率、未來市場趨勢預測(今後5年份)等調查,並將其結果為您概述為以下內容。

第1章 Tiotropium bromide的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的Tiotropium bromide市場概要

  • 專利及批審現況
  • 主要製造商
  • 市場規模

第3章 Tiotropium bromide的銷售額分析

  • 銷售額(以金額為準)
  • 銷售額(以數量為準)

第4章 主要廠商的市場佔有率分析

  • 市場佔有率(以金額為準)
  • 市場佔有率(以數量為準)

第5章 各劑型的市場規模分析

  • 各劑型的市場佔有率(以金額為準)
  • 各劑型的市場佔有率(以數量為準)

第6章 Tiotropium bromide的醫院用標準價格(各企業)

  • Boehringer Ingelheim
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Zhejiang Xianju Pharmaceutical Co., Ltd.

第7章 主要製造商分析

  • Boehringer Ingelheim
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
  • Zhejiang Xianju Pharmaceutical Co., Ltd.

第8章 中國的Tiotropium bromide市場未來展望

  • 市場規模的預測
  • 競爭情形的預測

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1506195

In recent years, various allergic diseases demonstrate an increasing trend under the influence of global environmental changes, leading to the occurrence of seasonal cough and asthma in winter and spring. Affected by tobacco, dust and pollutants, the incidence of chronic obstructive pulmonary disease (COPD) is still on the rise. COPD is a chronic pulmonary disease characterized by incompletely reversible airflow obstruction. The major clinical manifestations are recurrent cough, expectoration, dyspnea. COPD often demonstrate a progressive characteristic, including large parts of chronic bronchitis and emphysema.

According to a survey, the incidence of COPD among people aged above 40 is 8.2% on average and higher in men (12.4%) than in women (5.1%). The number of COPD cases in China has exceeded 40 million and 65 million people are expected to die of COPD during the period of 2003-2033.

For many years, the COPD market and anti-asthmatic agents market have been dominated by four big companies - GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca and Merck. They take up over 80% of respiratory agents market around the world while Novartis, Roche and Teva only occupy about 10%.

Tiotropium bromide, a long-acting anticholinergic drug for inhalation, was developed by Boehringer Ingelheim. It is the first inhaler that can offer significant and lasting lung function improvement after one dosage per day. Tiotropium bromide can exert positive influence on COPD's clinical course so as to help improve the state of patient's life. Therefore it is widely welcomed by patients and has become the drug with the largest prescriptions in the world for the treatment of COPD. The sales value of tiotropium bromide in global market in 2013 reached nearly USD 5 billion.

According to CRI's survey, tiotropium bromide develops fast after entering China with annual sales rising from less than CNY 1 million in 2006 to CNY 140 million in 2014 and CAGR reaching up to 90% during the period of 2006-2014. Currently, Tiotropium bromide in the Chinese market comes from the following three companies: Boehringer Ingelheim (Germany), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Zhejiang Xianju Pharmaceutical Co., Ltd, among which Boehringer Ingelheim (Germany) has the largest market share of over 80% with sales value reaching up to CNY 114 million in 2014.

It is expected that in the next few years, tiotropium bromide market in China will keep expanding fast.

Readers can get at least the following information through this report:

  • market share of manufacturers of tiotropium bromide in Chinese hospitals
  • price of tiotropium bromide in Chinese hospitals
  • major manufacturers of tiotropium bromide in Chinese market
  • share of different dosage forms of tiotropium bromide in Chinese hospitals
  • market outlook of tiotropium bromide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of COPD drugs
  • investors interested in China COPD drug market

Table of Contents

1. Related Concepts of Tiotropium Bromide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Tiotropium Bromide in China

  • 2.1. Patent and Approval Status of Tiotropium Bromide in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Tiotropium Bromide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Tiotropium Bromide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Tiotropium Bromide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Tiotropium Bromide in Chinese Hospitals in 2014

  • 6.1. Boehringer Ingelheim (Germany) (Trade Name: Spiriva)
  • 6.2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Sule)
  • 6.3. Zhejiang Xianju Pharmaceutical Co., Ltd (Trade Name: Biduoyi)

7. Major Manufacturers of Tiotropium Bromide in Chinese Market, 2010-2014

  • 7.1. Boehringer Ingelheim (Germany)
  • 7.2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • 7.3. Zhejiang Xianju Pharmaceutical Co., Ltd

8. Market Outlook of Tiotropium Bromide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Tiotropium Bromide in China
  • Chart Approval Information of Tiotropium Bromide in China
  • Chart Sales Status of Tiotropium Bromide in Chinese Market, 2010-2014
  • Chart Sales Value of Tiotropium Bromide in China, 2010-2014
  • Chart Sales Value of Tiotropium Bromide in Some Regions in China, 2010-2014
  • Chart Sales Volume of Tiotropium Bromide in China, 2010-2014
  • Chart Market Share of Top3 Manufacturers of Tiotropium Bromide for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Tiotropium Bromide Made by Boehringer Ingelheim (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Tiotropium Bromide Made by Chia Tai Tianqing in China, 2010-2014
  • Chart Sales Value and Market Share of Tiotropium Bromide Made by Xianju Pharmaceutical in China, 2010-2014
  • Chart Price of Tiotropium Bromide Made by Boehringer Ingelheim (Germany) in Some Chinese Cities in 2014
  • Chart Price of Tiotropium Bromide Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Tiotropium Bromide Made by Zhejiang Xianju Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top